VERU INC. Form 8-K Summary
Business Context and Reporting Period
On September 19, 2024, VERU INC. (the "Company") filed a Current Report on Form 8-K regarding a material definitive agreement. The filing concerns an amended forbearance arrangement with Onconetix, Inc. (formerly Blue Water Vaccines Inc., the "Borrower"), stemming from payment obligations under an Asset Purchase Agreement dated April 19, 2023.
Key Financial Metrics and Debt Obligations
The filing details two promissory notes issued by the Borrower to the Company:
- April 2024 Promissory Note: Principal amount of $5,000,000, originally due April 19, 2024.
- September 2024 Promissory Note: Principal amount of $5,000,000, originally due September 30, 2024.
The filing does not provide specific revenue, profit, cash flow, or liquidity metrics for VERU INC. itself, as the report focuses on the terms of the receivable agreement.
Material Changes and Agreement Terms
The Company entered into an Amended and Restated Forbearance Agreement on September 19, 2024, modifying the original April 2024 agreement. Key changes include:
- Forbearance Period Extension: The period during which the Company forbears from exercising remedies for the April 2024 Note default is extended to the earlier of March 31, 2025, or an Event of Default.
- Maturity Extension: The due date for the September 2024 Promissory Note is extended to the earlier of June 30, 2025, or an Event of Default.
- Increased Payment Requirements:
- Monthly payments increased to 25% (from 15%) of the Borrower's cash receipts from sales or licensing, effective October 20, 2024.
- Payments from net proceeds of financing transactions increased to 20% (from 10%), effective for proceeds received after September 19, 2024.
- Interest Accrual: The September 2024 Note will accrue interest at 10% per annum on unpaid principal starting October 1, 2024.
- Payment Method: Obligations may be satisfied in cash or, with mutual consent, in shares of the Borrower's common stock.
- Early Repayment Incentive: If all principal and interest on both notes are repaid in cash by December 31, 2024, the principal balance of the September 2024 Note is reduced from $5,000,000 to $3,500,000.
Outlook, Risks, and Contingencies
The filing explicitly states there can be no assurance regarding:
- Whether or when the Company will receive payments under the Amended Forbearance Agreement.
- The extent of the risk of future default by the Borrower on its payment obligations.
The agreement is contingent on the Borrower avoiding an "Event of Default" as defined in the amended terms.
Key Facts for Investor Verification
- Verify the Borrower's (Onconetix, Inc.) current financial health and ability to generate the cash receipts required for the increased 25% monthly payment.
- Monitor whether the Borrower can achieve the December 31, 2024, cash repayment deadline to trigger the $1.5 million principal reduction on the September 2024 Note.
- Assess the risk of the Borrower defaulting again before the new maturity dates of March 31, 2025, or June 30, 2025.
- Review the full text of the Amended Forbearance Agreement (Exhibit 10.1) for specific definitions of "Event of Default" and "cash receipts."